27 Results for "

EPR

" in MedChemExpress (MCE) Product Catalog:
Products (27)

27 Results for "EPR" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P7011
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EREG; Alternative Protein EREG; Epiregulin; EPR; ER; Ep; Proepiregulin
Species:  
Human
Source:  
E. coli
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136265
CAS No.: 695207-56-8
Purity:  99.20%
Research Areas:  

Cancer

BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P73031
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: EREG; Alternative Protein EREG; Epiregulin; EPR; ER; Ep; Proepiregulin
Species:  
Human
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P75226
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EREG; Alternative Protein EREG; Epiregulin; EPR; ER; Ep; Proepiregulin
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-168943
PLGA nanoparticles, 100nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 100nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 100nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 100nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research .
loading...
    loading...
Cat. No.: HY-RS16966
Research Areas:  

Others

Ereg Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ereg gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS04451
Research Areas:  

Others

EPRS1 Human Pre-designed siRNA Set A contains three designed siRNAs for EPRS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS04487
Research Areas:  

Others

EREG Human Pre-designed siRNA Set A contains three designed siRNAs for EREG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-147151
CAS No.: 439858-38-5
Research Areas:  

Others

AMCPy is a potent electron paramagnetic resonance (EPR) brain imaging agent, possessing excellent lipophilicity for blood brain barrier (BBB) penetration .
loading...
    loading...
Cat. No.: HY-174692
Target:  

mRNA

Research Areas:  

Cancer

Human FGF8 mRNA encodes the human fibroblast growth factor 8 (FGF8) protein, a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion.
loading...
    loading...
Cat. No.: HY-174547
Target:  

mRNA

Research Areas:  

Metabolic Disease

Human PDX1 mRNA encodes the human pancreatic and duodenal homeobox 1 (PDX1) protein, a transcriptional activator of several genes, including insulin, somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2. PDX1 may be involved in the early development of the pancreas. It also plays a major role in glucose-dependent regulation of insulin gene expression.
loading...
    loading...
Cat. No.: HY-W777072
CAS No.: 88418-69-3
Target:  

HIV

Research Areas:  

Others

4-isocyanato TEMPO is a spin labeling reagent used to label the 2’-position in RNA. It has been used to study HIV-1 transactivation response RNA and hammerhead ribosome dynamics by electron paramagnetic resonance (EPR) spectroscopy.
loading...
    loading...
Cat. No.: HY-168943A
PLGA nanoparticles, 200nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 200nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 200nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 200nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research .
loading...
    loading...
Cat. No.: HY-168943B
PLGA nanoparticles, 500nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 500nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 500nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 500nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research .
loading...
    loading...
Cat. No.: HY-168943C
PLGA nanoparticles, 1μm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 1μm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 1μm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 1μm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research .
loading...
    loading...
Cat. No.: HY-P83830
Synonyms: API4; EPR-1

Host:  

Mouse

Application:  

WB, IHC-P, ICC/IF, FC, ELISA

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P83830A
Synonyms: API4; EPR-1

Host:  

Mouse

Application:  

WB, IHC-P, ICC/IF, FC, ELISA

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P83039
Synonyms: Elf3; EPR1; ERT; ESE-1; ESX; jen

Host:  

Rabbit

Application:  

WB, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-P77769
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha; EPR1
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P77770
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha; EPR1
Species:  
Human
Source:  
HEK293
loading...
    loading...